Refer to this page for the latest educational resources and information on lenzilumab as a therapeutic for cytokine storm resulting from COVID-19 infection.

Visit To learn about Humanigen's Phase 3 Clinical Trial

Follow us on Twitter

Learn how Lenzilumab™ may reduce serious or fatal outcomes in COVID-19 patients

In the News

FOX 5 Atlanta: New drug to fight COVID-19 symptoms

Radio Interview | KISS 104.1 Atlanta

Humanigen's Dr. Cameron Durrant Joins KISS 104.1

Research | J Transl Med

The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

Podcast | JAMA Network

COVID-19 Update—Critical Care and Pandemic Response

News | KXAN

Austin hospitals to help test new COVID-19 treatment

Perspective | NEJM

Bridging the Gap at Warp Speed — Delivering Options for Preventing and Treating Covid-19

Article | BioCentury

Warp Speed’s Slaoui expects two COVID-19 vaccines this year

Article | Am J Respir Crit Care Med.

Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 ARDS

Article | BioWorld

Snowballing research preps avalanche to bury COVID-19

Preprint | medRxiv

First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia

Interview | Proactive Investors

Humanigen CEO Discusses Phase III Trial for Lenzilumab in COVID-19 Patients

Article | The New York Times

The Coronavirus Patients Betrayed by Their Own Immune Systems

Graphic | Reuters

Ventilators: a bridge between life and death?

Research Letter | JAMA

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Preprint | IHME

Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator days and deaths

Opinion | Bloomberg

Coronavirus: Why Surgeons Don't Want to Operate Right Now

Preprint | Cell Press

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Preprint | bioRxiv

GM-CSF and Cytokine Storm in Coronavirus

Research | JAMA Internal Medicine

Acute Respiratory Distress Syndrome and Death in Coronavirus Patients

Article | BioWorld

Humanigen preps lenzilumab for battle with COVID-19 symptom

Supplemental information | The Lancet

Data on immunology and inflammation in COVID-19

Article | The Atlantic

Why the Coronavirus Has Been So Successful

Review | American Society for Microbiology

Into the Eye of the Cytokine Storm

Article | Evaluate

Tiziana takes a deep breath and targets Covid-19

Preprint | medRxiv

Lung bronchoalveolar immune cells in COVID-19

Journal | The Lancet

Clinical features of coronavirus patients in Wuhan, China

Article | STAT

Researchers rush to test vaccine in humans without animal testing

Article | MIT Technology Review

A coronavirus vaccine will take at least 18 months—if it works at all

Humanigen Publication | blood

GM-CSF inhibition reduces cytokine release syndrome

Article | National Geographic

Here’s what coronavirus does to the body

Research | The Journal of Immunology

GM-CSF but Not IL-17 Critical for Development of Interstitial Lung Disease in Mice

Follow Us

  • Twitter
  • LinkedIn
  • Facebook

©2021 Humanigen, Inc.  All rights reserved